April 2, 2026 5:00 am EDT Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
February 6, 2026 7:00 am EST Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025